|Mr. Joshua N. Silverman||Exec. Chairman||N/A||N/A||1970|
|Mr. Christopher C. Schreiber||Pres, CEO & Director||N/A||N/A||1965|
|Dr. Christopher C. Chapman Jr.||Pres & Chief Medical Officer||N/A||N/A||1953|
|Mr. Paul Rivard Esq.||VP of Operations & Gen. Counsel||N/A||N/A||N/A|
|Dr. Adam Kaplin M.D., Ph.D.||Chief Scientific Officer||N/A||N/A||1967|
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, engages in the development of drug candidates to treat autoimmune, and aging and age-related diseases. It is developing MYMD-1, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel diseases, as well as to treat age-related illnesses such as, frailty and sarcopenia. The company is also developing Supera-CBD, a synthetic preclinical cannabidiol derivative that targets CB2 receptors. The company is based in Baltimore, Maryland.
MyMD Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.